A scoring system for prescribing fidaxomicin in Clostridium diffícile infection.
Recurrences of Clostridium difficile infections lead to hospital readmissions and high costs, in addition to the suffering and frustration for the patients. Fidaxomicin has recently been introduced as a new antibiotic that has been shown to significantly reduce the recurrence of this infection. Despite this superiority, its high cost has led to very restrictive policies in its use, as such that many institutions only use it in patients with multiple recurrences. While waiting for new predictive clinical tools, we propose the development of scoring systems that allow the more high-risk patients to be treated earlier.
Servicio de Enfermedades Infecciosas, Hospital Ramón y Cajal, Madrid, España. Electronic address: mjesus.vivancos@gmail.com.
María Jesús
MJ
Vivancos-Gallego
Servicio de Urgencias, Hospital 12 de Octubre, Madrid, España.
M Ángeles
MÁ
Jiménez-López
Servicio de Medicina Interna, Hospital Ramón y Cajal, Madrid, España.
Francesca
F
Gioia
Servicio de Medicina Interna, Hospital Ramón y Cajal, Madrid, España.
Dione
D
Ibañez-Segura
Servicio de Microbiología, Hospital Ramón y Cajal, Madrid, España.
José
J
Romero-Vivas
Servicio de Enfermedades Infecciosas, Hospital Ramón y Cajal, Madrid, España.
Javier
J
Cobo
D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D003015:Clostridium Infections / Q000188:drug therapy*; D005260:Female; D000077732:Fidaxomicin / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D018579:Patient Selection; D012008:Recurrence; D018570:Risk Assessment
D000900:Anti-Bacterial Agents; D000077732:Fidaxomicin
Clostridium difficile; Fidaxomicin; Fidaxomicina; Recurrences; Recurrencia